Top insider buys and sells disclosed on Tuesday
Insider trading activity for US-listed stocks on Tuesday included significant purchases and sales. Saba Capital bought 338,104 shares of BNY Mellon Strategic Municipals (LEO) at $5.63-$5.67. Nippon Life bought 347,195 shares of Corebridge Financial (CRBG) at $34.31-$35.07. Kevin Tang increased his stake in Boundless Bio (BOLD) with purchases totaling $349,592. Smriti Popenoe bought $156,560 of Dynex Capital (DX) stock. David Sims acquired $108,632 of Eagle Capital Growth Fund (GRF) shares.
How this was made
The 30-second read
Why it matters
While individual transactions vary in size, the overall mix of buys and sells offers limited actionable insight for traders, serving more as a monitoring tool.
Market read
Insider activity provides modest signals; no single catalyst drives market moves.
What to watch
Some purchases are by directors with fiduciary duties, which may carry more weight than typical insider buys.
Background
The article aggregates recent Form 4 filings for a range of U.S. listed companies, highlighting both insider purchases and sales.
Ticker impact
Saba Capital increased its stake in LEO with purchases totaling 338,104 shares at $5.63‑$5.67 each.
likely modest upside as the market prices in insider confidence
Significant purchase by a director‑shareholder signals confidence in dividend yield and stability.
Nippon Life Insurance, a 10% owner, bought 347,195 shares of CRBG under a 10b5‑1 plan.
potential upward pressure, especially near recent 52‑week high
Purchase adds to already sizable ownership, reinforcing confidence in recent price gains.
Director Kevin Tang increased his stake in BOLD with purchases totaling about $350k.
limited upside, likely neutral to modestly bullish
Small relative to market cap; signals personal confidence but limited market impact.
Co‑CEO Smriti Laxman Popenoe bought 10,000 shares and 2,000 preferred shares of DX for $156,560.
potential modest upside as investors note insider confidence near 52‑week low
Purchase occurs near a price trough, suggesting belief in upside.
Eagle Capital Growth Fund CFO David Sims bought $108,632 of GRF shares.
likely neutral to mildly bullish
Purchase size modest; may be seen as confidence but limited market effect.
UiPath CEO Daniel Dines sold 2.5 million PATH shares for $33 M via a 10b5‑1 plan.
downward pressure as market digests sizable sell‑off
Sale represents a significant portion of float and may signal concerns.
Micron CTO Scott Deboer sold 28,544.572 MU shares for $25.7 M under a 10b5‑1 plan.
potential modest downside as investors note insider liquidation
Sell size is notable but not a large fraction of market cap.
Trustee Robert Young sold all 16,131 NZF shares (~$17.6 M) via a 10b5‑1 plan.
likely pressure, especially near 52‑week low
Full divestiture by a trustee could be interpreted as lack of confidence.
Market effects
Insider activity across financial services, biotech, and technology suggests mixed confidence signals but no sector‑wide trend.
Primarily U.S. equity market; limited broader regional effect.
Low global impact; reflects routine insider transactions.
Counterpoint
Large insider sells may be overstated; could reflect personal liquidity needs rather than company outlook.
Key entities
- investment firmSaba Capital Management
Increased stake in LEO
- institutional investorNippon Life Insurance
Bought shares of CRBG
- executiveDaniel Dines
Sold large position in PATH
